Premium
Proof‐of‐concept trial on the efficacy of sodium tungstate in human obesity
Author(s) -
Hanzu F.,
Gomis R.,
Coves M. J.,
Viaplana J.,
Palomo M.,
Andreu A.,
Szpunar J.,
Vidal J.
Publication year - 2010
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2010.01293.x
Subject(s) - sodium tungstate , placebo , medicine , body mass index , randomization , obesity , sodium , tungstate , clinical endpoint , randomized controlled trial , endocrinology , chemistry , alternative medicine , organic chemistry , pathology , tungsten
Aim: Considering the poor long‐term success of current dietary and pharmacological interventions, we aimed to evaluate the potential effect of sodium tungstate in the treatment of grade I and II obesity ( ClinicalTrials.gov identifier: NCT00555074). Methods: Prospective, randomized, placebo‐controlled, double‐blind, proof‐of‐concept study was carried out. Following a 2‐week lead‐in period, 30 obese (body mass index, BMI 30.0–39.9 kg/m 2 ), non‐diabetic subjects were randomized to receive either sodium tungstate (100 mg bid) or placebo for 6 weeks. The primary study endpoint was the absolute change in body weight relative to the time of randomization. Results: Treatment with sodium tungstate [−0.135 ± 0.268 kg (95% CI −0.686 to +0.416 kg)] was not associated with a significant weight loss compared to placebo [−0.063 ± 0.277 kg (95% CI −0.632 to +0.507 kg)] (p = 0.854). Likewise, treatment with sodium tungstate was not associated with significant changes in fat mass (DEXA), resting energy expenditure (indirect calorimetry) or caloric consumption (3‐day food records). Conclusion: Our data do not support sodium tungstate as a pharmacological agent in the treatment of human obesity.